A Modular Open-label Phase I/II Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Ret Fusion-positive Nsclc, : Ret Mutation-positive Mtc
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Documented RET-altered malignancy as determined by a DNA- or RNA-based assay of tumour tissue and/or a liquid biopsy
    2. Tissue or liquid biopsy at screening for retrospective confirmation of RET aberration status, after progression on first-generation SRI
    3. Ability to swallow and retain oral medication

You may not be eligible for this study if the following are true:

    1. Any other known major driver gene alterations except RET
    2. Any other invasive malignancy which has been active or treated within the past 3 years
    3. Spinal cord compression or unstable brain metastases

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.